Bliss GVS Pharma Ltd logo

Bliss GVS Pharma Ltd

BLISSGVS NSE

Key Fundamentals

MicrocapPharmaceuticalsHealthcare
Market Cap
₹5,397 Cr
Volatility
Moderate
P/E Ratio
42.5
EBITDA
₹238 Cr
Return on Equity
10.94%
Debt to Equity
0.02
Book Value
₹112.25
52W High
₹553
52W Low
₹118

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Bliss GVS Pharma Ltd insights

37 extracted metrics + investor summaries across FY15–FY26.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Strengths

2
  • Company has reduced debt.
  • Company is almost debt free.

Weaknesses

4
  • Stock is trading at 4.62 times its book value
  • The company has delivered a poor sales growth of 9.94% over past five years.
  • Company has a low return on equity of 10.2% over last 3 years.
  • Company has high debtors of 204 days.

Growth Rate

Revenue Growth
18.25% ↗
Net Income Growth
49.17% ↗
Cash Flow Change
30.98% ↗
ROE
32.29% ↘
ROCE
35.36% ↘
EBITDA Margin (Avg.)
23.13% ↘

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 42d ago
AI opinion · based on fundamentals
Risk high

Bliss GVS Pharma Ltd is a near debt-free pharmaceutical company with a market cap of Rs.5,385 Cr trading at a PE of 39.8x. The stock has delivered a 224% return over the past year driven by a 56% TTM profit growth, though underlying sales growth remains modest at 15% TTM and 5-year CAGR of 10%.

Bull Case 7
  • Company is almost debt-free, having actively reduced its debt, which strengthens the balance sheet and lowers financial risk
  • TTM profit growth of 56% indicates a sharp acceleration in earnings relative to the 5-year profit CAGR of 14%
  • Stock has delivered a 1-year return of 224%, reflecting strong market re-rating and momentum
  • 3-year compounded profit growth of 23% outpaces 3-year sales growth of 7%, suggesting improving operating leverage and margins
  • ROE has improved to 12% in the last year from a 3-year average of 10% and 5-year average of 9%, indicating an upward trajectory in capital efficiency
  • TTM sales growth of 15% marks an acceleration from the 10-year compounded sales CAGR of just 5%
  • 5-year stock CAGR of 35% and 10-year CAGR of 17% demonstrate sustained long-term wealth creation
Bear Case 8
  • PE ratio of 39.8x is elevated for a company with 5-year sales CAGR of only 10%, suggesting the stock may be pricing in optimistic growth assumptions
  • Debtor days stand at 204 days, indicating significant working capital locked in receivables and potential collection risk
  • Other income of Rs.67.5 Cr forms a material portion of earnings, meaning core operating profit may be lower than headline numbers suggest
  • Price-to-book ratio of 4.49x is high relative to the 3-year ROE of only 10.2%, implying the market is paying a premium not fully justified by returns on equity
  • 5-year compounded sales growth of approximately 10% and past 5-year reported sales growth of 9.94% remain below peer benchmarks in the pharma sector
  • 3-year ROE of 10% is below the 15%+ threshold typically expected of quality compounders in healthcare
  • Dividend yield of only 0.3% offers negligible income support to investors at current valuations
  • After a 224% rally in one year, the stock's risk-reward is skewed — 52-week high/low data is unavailable, limiting visibility into downside support levels

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 42d ago
Positives 2
  • Strong FY26 revenue and profit Jun 23

    Consolidated revenue rose 18.26% YoY to ₹1,00,064.26 Lakh in FY26, with net profit surging 49.27% to ₹13,472.77 Lakh. Final dividend of ₹1.00 per share recommended.

  • Anupam Rasayan open offer at ₹299 Jun 9

    Anupam Rasayan announced an open offer to acquire up to 26.00% of Bliss GVS at ₹299.00 per share (₹829.03 crore), following a share purchase agreement for 43.30% stake.

Neutral 2
  • New CEO appointed from July 15 Jul 3

    Rahul Adakmol appointed CEO effective July 15, 2026, and Santosh Parab as Additional Director. Narsimha Kamath stepped down as CEO.

  • 41st AGM set for July 15 Jun 19

    Bliss GVS Pharma announced its 41st AGM on July 15, 2026, via video conferencing with ₹1.00 per share final dividend on the agenda.

TL;DR: Bliss GVS Pharma is executing well with 18% revenue growth and nearly 50% profit growth in FY26, signaling strong operational leverage. The Anupam Rasayan open offer at ₹299 per share provides a near-term floor and validates strategic value. Leadership transition to a new CEO introduces some execution uncertainty but no visible negatives. The trend is improving, with earnings momentum and potential strategic synergies from the acquisition likely to drive further interest.

Quarterly Results

  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
160
212
201
198
184
218
210
198
207
244
218
257
286
Expenses
135
158
157
170
149
176
181
177
166
201
183
213
209
Operating Profit
24
54
44
28
34
41
30
21
41
43
35
44
76
OPM %
15%
26%
22%
14%
19%
19%
14%
11%
20%
18%
16%
17%
27%
Other Income
5
13
5
-24
4
5
15
12
35
8
16
11
10
Interest
1
1
2
2
2
4
1
2
5
3
1
2
1
Depreciation
6
6
7
7
7
7
8
8
8
8
8
9
10
PBT
22
59
40
-4
30
36
36
23
63
41
41
45
75
Tax %
34%
27%
27%
24%
26%
28%
29%
29%
30%
30%
39%
18%
32%
Net Profit
14
43
29
-5
22
26
26
17
44
29
25
37
51
EPS in Rs
1.41
4.05
2.64
-0.87
1.97
2.31
2.26
1.47
4.08
2.58
2.2
3.36
4.72
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
407
547
798
815
899
689
577
747
752
770
810
927
1,005
Expenses
304
391
596
618
739
566
471
629
634
620
683
760
806
Operating Profit
103
156
203
197
160
123
107
118
117
151
127
168
199
OPM %
25%
29%
25%
24%
18%
18%
18%
16%
16%
20%
16%
18%
20%
Other Income
20
24
12
-8
35
26
20
-42
18
0
36
67
45
Interest
16
19
20
23
4
8
6
5
10
7
8
12
7
Depreciation
11
13
20
21
9
13
17
17
19
26
29
33
35
PBT
96
148
175
145
182
129
104
54
106
117
126
190
202
Tax %
36%
32%
36%
39%
30%
26%
29%
57%
28%
30%
28%
29%
—
Net Profit
61
100
113
89
127
95
74
23
77
82
90
135
142
EPS in Rs
5.81
8
7.95
5.7
11.99
9.43
6.64
1.45
6.8
7.21
8
12.21
12.86
Div. Payout %
12%
6%
8%
18%
8%
5%
8%
34%
7%
7%
6%
4%
—
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
10
10
10
10
10
10
10
10
10
10
11
11
Reserves
327
402
476
526
636
725
798
808
873
957
1,040
1,182
Borrowings
160
132
225
118
102
126
122
109
102
100
88
22
Other Liabilities
166
218
311
206
157
168
147
181
171
145
163
278
Total Liabilities
662
762
1,023
860
905
1,030
1,077
1,109
1,157
1,212
1,301
1,492
Fixed Assets
234
225
305
143
146
242
234
281
379
370
406
459
CWIP
0
9
4
0
47
0
2
22
3
8
21
6
Investments
0
0
0
0
0
0
0
2
8
4
4
5
Other Assets
428
527
714
717
712
788
840
803
768
830
871
1,022
Total Assets
662
762
1,023
860
905
1,030
1,077
1,109
1,157
1,212
1,301
1,492
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
38
113
289
18
40
47
64
135
34
103
106
139
Investing
-29
-50
-249
48
-79
-40
-45
-103
-6
-83
-75
-38
Financing
-42
-40
-10
-76
17
-6
-21
-24
-25
-21
-30
-89
Net Cash Flow
-34
23
30
-10
-22
0
-2
9
3
-1
0
11
Free Cash Flow
5
101
186
-7
2
-12
55
63
-59
75
33
84
CFO/OP
45
101
160
29
-8
69
87
143
67
91
112
108
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
222
201
116
134
187
290
293
192
187
192
198
204
Inventory Days
69
55
50
55
46
64
110
116
94
113
111
129
Days Payable
165
153
100
55
47
75
82
86
79
58
63
89
Cash Conversion Cycle
126
102
67
134
186
279
321
221
202
247
246
244
Working Capital Days
105
84
-10
135
154
232
264
179
192
207
198
214
ROCE %
23%
31%
29%
27%
26%
18%
12%
14%
12%
14%
12%
17%

Shareholding Pattern

As of Jun 2026
Promoters 35.01%
Public 29.77%
Others 17.68%
DIIs 9.47%
FIIs 8.07%
Total 100.00%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
33.31%
33.24%
33.19%
33.14%
33.14%
34.51%
34.55%
34.46%
35.04%
35.12%
35.06%
34.97%
34.97%
34.90%
34.82%
35.10%
35.29%
35.44%
35.39%
35.36%
35.36%
35.01%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
16.31%
0.00%
14.73%
13.25%
12.13%
13.51%
13.18%
12.65%
13.27%
14.54%
10.45%
8.07%
DIIs
6.72%
6.72%
6.67%
6.66%
6.66%
6.65%
6.64%
6.63%
6.63%
6.62%
6.61%
6.59%
6.59%
6.58%
6.57%
6.55%
6.55%
6.54%
5.98%
5.78%
5.04%
9.47%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
23.45%
26.90%
27.59%
28.26%
30.37%
30.15%
30.57%
30.74%
30.00%
30.10%
29.17%
30.78%
31.71%
32.84%
34.57%
32.93%
32.63%
32.79%
32.85%
31.48%
32.60%
29.77%
Others
36.52%
33.14%
32.55%
31.95%
29.84%
28.69%
28.24%
28.18%
28.33%
28.15%
12.84%
27.66%
12.00%
12.43%
11.92%
11.91%
12.34%
12.58%
12.51%
12.84%
16.55%
17.68%
No. of Shareholders
28,543
39,999
42,742
41,080
45,866
46,327
45,753
44,983
43,041
42,182
43,234
40,758
45,157
44,737
52,937
49,558
49,517
46,707
44,461
43,380
44,874
46,767

Documents

1
Concall - Jan 2018 Jan 2018
2
Concall - May 2018 May 2018
3
Concall - Aug 2018 Aug 2018
4
Concall - Nov 2018 Nov 2018
5
Concall - Feb 2019 Feb 2019

Frequently Asked Questions about Bliss GVS Pharma Ltd

What does Bliss GVS Pharma Ltd do?
Incorporated in 1984, Bliss GVS Pharma Limited is engaged in manufacturing, marketing, trading and export of pharmaceutical formulations in the form of suppositories, pessaries, capsules, tablets, and syrups.
Where is Bliss GVS Pharma Ltd (BLISSGVS) listed?
Bliss GVS Pharma Ltd is listed on the Indian stock exchanges. It is listed on NSE: BLISSGVS and BSE: 506197. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Bliss GVS Pharma Ltd belong to?
Bliss GVS Pharma Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Bliss GVS Pharma Ltd?
Bliss GVS Pharma Ltd has a market capitalisation of approximately ₹5397.35 Cr. Based on this, it is classified as a Mid Cap stock.
What is the PE ratio of Bliss GVS Pharma Ltd?
The Price-to-Earnings (PE) ratio of Bliss GVS Pharma Ltd is 42.50. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Bliss GVS Pharma Ltd?
Over the past 52 weeks, Bliss GVS Pharma Ltd has traded between a low of ₹118 and a high of ₹553. This range helps investors understand the stock's price volatility and recent trading levels.
Does Bliss GVS Pharma Ltd pay dividends?
Yes, Bliss GVS Pharma Ltd has a dividend yield of 0.29%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Bliss GVS Pharma Ltd?
Bliss GVS Pharma Ltd has a Return on Equity (ROE) of 10.94%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Bliss GVS Pharma Ltd on Tapetide?
On Tapetide, you can view Bliss GVS Pharma Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Incorporated in 1984, Bliss GVS Pharma Limited is engaged in manufacturing, marketing, trading and export of pharmaceutical formulations in the form of suppositories, pessaries, capsules, tablets, and syrups.

Website blissgvs.com
CEO Dr. Vibha Gagan Sharma
Employees 966
Listed 2010-07-30
Face Value ₹ 1
Issued Size 10,57,88,972

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List